For research use only. Not for therapeutic Use.
QM295（Cat No.:I042301）is a selective small molecule inhibitor designed to target and inhibit the protein kinase c-Abl (also known as Abelson murine leukemia viral oncogene homolog 1), which is implicated in various cancers, including chronic myelogenous leukemia (CML). By blocking the activity of c-Abl, QM295 aims to prevent the aberrant signaling pathways that promote tumor growth and resistance to treatment. It has shown promise in preclinical studies for overcoming resistance to other tyrosine kinase inhibitors, potentially offering a new therapeutic option in the treatment of c-Abl-driven cancers.
| Catalog Number | I042301 |
| CAS Number | 1241046-32-1 |
| Synonyms | (4Z)-4-[(4-hydroxy-3-methoxyphenyl)methylidene]-3-phenyl-1,2-oxazol-5-one |
| Molecular Formula | C17H13NO4 |
| Purity | ≥95% |
| IUPAC Name | (4Z)-4-[(4-hydroxy-3-methoxyphenyl)methylidene]-3-phenyl-1,2-oxazol-5-one |
| InChI | InChI=1S/C17H13NO4/c1-21-15-10-11(7-8-14(15)19)9-13-16(18-22-17(13)20)12-5-3-2-4-6-12/h2-10,19H,1H3/b13-9- |
| InChIKey | LRCZCFNUNZQGGK-LCYFTJDESA-N |
| SMILES | COC1=C(C=CC(=C1)/C=C\2/C(=NOC2=O)C3=CC=CC=C3)O |
